(Q34521606)

2 August 2017

1 reference

title

Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia (English)

1 reference

2 August 2017

0 references

Glen L Stimmel

1

1 reference

2 August 2017

Mary A Gutierrez

series ordinal

2

1 reference

2 August 2017

Vivian Lee

series ordinal

3

1 reference

2 August 2017

publication date

1 January 2002

1 reference

2 August 2017

published in

Clinical Therapeutics

1 reference

2 August 2017

volume

24

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

21-37

1 reference

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

Ziprasidone and the pharmacokinetics of a combined oral contraceptive

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

Prolactin and antipsychotic medications: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

Olanzapine increases weight and serum triglyceride levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

The apparent effects of ziprasidone on plasma lipids and glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

Novel antipsychotics and new onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985003-2

1 reference

7 January 2021

10.1016/S0149-2918(02)85003-2

Identifiers

DOI

1 reference

2 August 2017

1 reference